Skip to main content

TScan Therapeutics, Inc.

TCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001783328

No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding TScan Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of TCRX: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders3254+22
Shares28.6M31.9M+3.32M (+11.6%)
Value$73.2M$186.1M+$112.9M (+154.2%)

New holders (22)

Institutions that held TScan Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to TCRX in Q4 2023
InstitutionSharesValue% of portfolio
Propel Bio Management, LLC2,087,139$12.2M10.09%
Standard Life Aberdeen plc200,000$1.17M0.00%
Marshall Wace, LLP110,551$644.5K0.00%
Millennium Management LLC99,082$577.6K0.00%
Jane Street Group, LLC83,622$487.5K0.00%
Citigroup Inc73,163$426.5K0.00%
ExodusPoint Capital Management, LP63,778$372.0K0.00%
Laurion Capital Management LP60,400$352.1K0.01%
Man Group plc50,410$293.9K0.00%
Balyasny Asset Management LLC45,986$268.1K0.00%
683 Capital Management, LLC43,198$251.8K0.03%
JPMorgan Chase & Co33,230$193.7K0.00%
Goldman Sachs Group Inc30,285$176.6K0.00%
Cubist Systematic Strategies, LLC26,245$153.0K0.00%
Charles Schwab Investment Management Inc22,104$128.9K0.00%
Virtu Financial LLC18,418$107.0K0.01%
Walleye Capital LLC17,777$103.6K0.00%
Bank of New York Mellon Corp16,670$97.2K0.00%
Y-Intercept (Hong Kong) Ltd15,005$87.5K0.01%
Boothbay Fund Management, LLC13,293$77.5K0.00%
Lazard Asset Management LLC3,983$22.0K0.00%
Tower Research Capital LLC (TRC)43$2510.00%

Sold out (0)

Institutions that held TScan Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

None.